Oesophago-gastric cancer Cancer Oesophago-gastric cancer
Conditions
Interventions
Patients were randomised to one of the following groups:
Arm 1: enteral immune enhancing diet (IED) -
This group received IED (Oxepa), seven days pre- and post-operatively. Oxepa is a complete bala
Sponsors
The Northern Oesophago-Gastric Cancer Unit (NOGCU) (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients (either sex) presenting to two tertiary centres, between April 2003 to January 2007, with histologically proven oesophageal or gastric malignancy and who were suitable for subtotal oesophagectomy or total gastrectomy with curative intent were eligible for the study.
Exclusion criteria
Exclusion criteria: 1. Less than seven days time from recruitment to operation date 2. Metastatic or unresectable disease 3. Respiratory tract dysfunction (partial pressure of oxygen in arterial blood [PaO2] less than 70 mmHg) 4. Cardiac dysfunction (New York Heart Class greater than three) 5. Hepatic dysfunction (Child-Pugh score greater than B) 6. Concurrent infection 7. Pregnancy 8. Aged less than 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of infective complications. Infective and non-infective complications were noted and graded daily up until discharge. Complications were defined as those published previously (Bozzetti, Braga et al. 2001). This was collected consistently by two full time research registrars designated to the trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-infective complications, mortality, duration of hospital stay and nutritional status: 1. Jejunostomy/feeding-related complications: recorded daily till discharge 2. Antibiotic usage: the duration of both prophylactic and therapeutic antibiotic usage was noted 3. Length of hospital and critical care stay 4. Mortality: both in hospital and 30 days post-operatively was recorded 5. Concentration of fatty acids in plasma 6. Nutritional status: recorded by two dieticians such as weight, BMI, triceps skin fold thickness and mid-arm muscle circumference | — |
Countries
United Kingdom
Outcome results
None listed